Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP691354.RAB0_FyvlM_bskDu9vVHpQWUvUfmP7kTXlCL6-MydOFi0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP691354.RAB0_FyvlM_bskDu9vVHpQWUvUfmP7kTXlCL6-MydOFi0130_assertion type Assertion NP691354.RAB0_FyvlM_bskDu9vVHpQWUvUfmP7kTXlCL6-MydOFi0130_head.
- NP691354.RAB0_FyvlM_bskDu9vVHpQWUvUfmP7kTXlCL6-MydOFi0130_assertion description "[Our results suggest that the ER genomic pathway in the ER-positive and Herceptin-resistant breast cancer cells may be reactivated, allowing tamoxifen therapy to be effective again, and a combination of tamoxifen and Herceptin can be a potential therapeutic strategy for ER-positive and Herceptin-resistant human breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP691354.RAB0_FyvlM_bskDu9vVHpQWUvUfmP7kTXlCL6-MydOFi0130_provenance.
- NP691354.RAB0_FyvlM_bskDu9vVHpQWUvUfmP7kTXlCL6-MydOFi0130_assertion evidence source_evidence_literature NP691354.RAB0_FyvlM_bskDu9vVHpQWUvUfmP7kTXlCL6-MydOFi0130_provenance.
- NP691354.RAB0_FyvlM_bskDu9vVHpQWUvUfmP7kTXlCL6-MydOFi0130_assertion SIO_000772 18768663 NP691354.RAB0_FyvlM_bskDu9vVHpQWUvUfmP7kTXlCL6-MydOFi0130_provenance.
- NP691354.RAB0_FyvlM_bskDu9vVHpQWUvUfmP7kTXlCL6-MydOFi0130_assertion wasDerivedFrom befree-2016 NP691354.RAB0_FyvlM_bskDu9vVHpQWUvUfmP7kTXlCL6-MydOFi0130_provenance.
- NP691354.RAB0_FyvlM_bskDu9vVHpQWUvUfmP7kTXlCL6-MydOFi0130_assertion wasGeneratedBy ECO_0000203 NP691354.RAB0_FyvlM_bskDu9vVHpQWUvUfmP7kTXlCL6-MydOFi0130_provenance.